A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: KCNT1-Related Epilepsy

In brief

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Key facts

Study ID

NCT07600736

Run by

Actio Biosciences, Inc.

People needed

55

Starts

2026-05-18

Expected to finish

2028-01-01

Last updated by the study team

2026-08-07

Who can join

Age: 0 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 1 month to <22 years
• Clinician-confirmed diagnosis of KCNT1-related epilepsy
• Has an average of at least 4 countable motor seizures per week
• Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2

You may not qualify if…

• Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine
• Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.

Where it is running

• Northeast Regional Epilepsy Group — Hackensack, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.